Adaptive Biotechnologies Corp
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(159,595) | $(225,304) | $(200,368) |
| Other comprehensive (loss) income | |||
| Change in unrealized gains and losses on investments | (49) | 4,331 | (2,979) |
| Comprehensive loss | (159,644) | (220,973) | (203,347) |
| Add: Comprehensive loss attributable to noncontrolling interest | 103 | 54 | 177 |
| Comprehensive loss attributable to Adaptive Biotechnologies Corporation | $(159,541) | $(220,919) | $(203,170) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.